West Pharmaceutical Services WST shares have gained 36.1% year to date, significantly outperforming its industry's advancement of 7.8%. The rally reflects improving demand for high-value pharmaceutical packaging components, stronger-than-expected earnings, and an upward revision to full-year guidance.
West Pharmaceutical Services remains a buy despite a demanding valuation, driven by new growth catalysts and robust financial performance. Double-digit growth from GLP-1s, HVP upgrades, and the multiyear Annex 1 regulatory opportunity underpin WST's bullish outlook. Annex 1 upgrades represent a multiyear, regulatory-driven mix shift, with only ~1B of a 6B component opportunity converted so far.
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michel Lagarde CEO | XHAN Exchange | US9553061055 ISIN |
| US Country | 10,800 Employees | 29 Jul 2026 Last Dividend | 27 Sep 2013 Last Split | 13 Jan 1978 IPO Date |
West Pharmaceutical Services, Inc. is a leading global provider in the design, manufacturing, and sale of containment and delivery systems for injectable drugs and healthcare products. With a presence across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, the company operates through two primary segments: Proprietary Products and Contract-Manufactured Products. Founded in 1923 and headquartered in Exton, Pennsylvania, West Pharmaceutical Services, Inc. is dedicated to serving biologic, generic, and pharmaceutical drug companies, as well as pharmaceutical, diagnostic, and medical device companies through a comprehensive sales force, distribution network, contract sales agents, and regional distributors.